Climate Impact of Inhaler Formularies - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Environmental Effects of Inhaler Formulations

  • By

  • William B. Feldman

  • September 28, 2026

Share

Clinical Scorecard: Environmental Effects of Inhaler Formulations

At a Glance

CategoryDetail
ConditionAsthma and Chronic Obstructive Pulmonary Disease (COPD)
Key MechanismsInhaler emissions from various formulations impact environmental sustainability.
Target PopulationPatients with asthma and COPD requiring inhaler therapy.
Care SettingClinical settings managing chronic respiratory diseases.

Key Highlights

  • Inhalers for asthma and COPD generate emissions comparable to 530,000 cars annually.
  • SABAs, ICSs, and ICS-LABAs account for 98% of inhaler-associated emissions.
  • Insurance coverage for dry powder inhalers is limited, affecting patient access.
  • Cost-sharing differences between inhaler types may impact environmental outcomes.
  • Market competition influences pricing and availability of inhaler options.

Guideline-Based Recommendations

Diagnosis

  • Assess asthma and COPD severity to guide inhaler selection.

Management

  • Prescribe maintenance therapy consistent with clinical guidelines.

Monitoring & Follow-up

  • Evaluate patient adherence and inhaler technique regularly.

Risks

  • Consider environmental impact and cost-sharing when prescribing inhalers.

Patient & Prescribing Data

Individuals with asthma and COPD requiring inhaler therapy.

Cost and emissions vary significantly between metered-dose and dry powder inhalers.

Clinical Best Practices

  • Encourage the use of lower-emission inhalers when appropriate.
  • Address systemic barriers to accessing environmentally sustainable inhalers.
  • Consider patient out-of-pocket costs when prescribing inhalers.

Related Resources & Content

Original Source(s)

Climate Impact of Inhaler Formularies

  • by William B. Feldman

  • September 28, 2026

Related Content

Top 10 evidence-based essentials in pulmonology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

Oral Microbiome Richness Tied to CRS

A cross-sectional metagenomic study found greater oral microbiome richness among adults with chronic rhinosinusitis, particularly nonallergic chronic rhinosinusitis, while associations with asthma, airway inflammation, and most lung-function measures were inconsistent.